Cargando…
Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2
The COVID-19 global pandemic is caused by SARS-CoV-2, and represents an urgent medical and social issue. Unfortunately, there is still not a single proven effective drug available, and therefore, current therapeutic guidelines recommend supportive care including oxygen administration and treatment w...
Autores principales: | Longhitano, Lucia, Tibullo, Daniele, Giallongo, Cesarina, Lazzarino, Giacomo, Tartaglia, Nicola, Galimberti, Sara, Li Volti, Giovanni, Palumbo, Giuseppe Alberto, Liso, Arcangelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279248/ https://www.ncbi.nlm.nih.gov/pubmed/32443911 http://dx.doi.org/10.3390/ijms21103622 |
Ejemplares similares
-
IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis
por: Liso, Arcangelo, et al.
Publicado: (2022) -
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023) -
The Role of Inflammation and Inflammasome in Myeloproliferative Disease
por: Longhitano, Lucia, et al.
Publicado: (2020) -
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis
por: Longhitano, Lucia, et al.
Publicado: (2021) -
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
por: La Spina, Enrico, et al.
Publicado: (2023)